Correlation Between NovAccess Global and EPIRUS Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both NovAccess Global and EPIRUS Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NovAccess Global and EPIRUS Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NovAccess Global and EPIRUS Biopharmaceuticals, you can compare the effects of market volatilities on NovAccess Global and EPIRUS Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NovAccess Global with a short position of EPIRUS Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of NovAccess Global and EPIRUS Biopharmaceutica.

Diversification Opportunities for NovAccess Global and EPIRUS Biopharmaceutica

0.0

Correlation Coefficient

NovAccess Global  EPIRUS Biopharmaceutica

Pay attention - limited upside

The 3 months correlation between NovAccess and EPIRUS is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding NovAccess Global and EPIRUS Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EPIRUS Biopharmaceuticals and NovAccess Global is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NovAccess Global are associated (or correlated) with EPIRUS Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EPIRUS Biopharmaceuticals has no effect on the direction of NovAccess Global i.e., NovAccess Global and EPIRUS Biopharmaceutica go up and down completely randomly.

Pair Corralation between NovAccess Global and EPIRUS Biopharmaceutica

If you would invest  0.03  in NovAccess Global on December 4, 2024 and sell it today you would earn a total of  0.01  from holding NovAccess Global or generate 33.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

NovAccess Global  vs.  EPIRUS Biopharmaceuticals

NovAccess Global

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in NovAccess Global are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NovAccess Global showed solid returns over the last few months and may actually be approaching a breakup point.

EPIRUS Biopharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days EPIRUS Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, EPIRUS Biopharmaceutica is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with NovAccess Global and EPIRUS Biopharmaceutica

The main advantage of trading using opposite NovAccess Global and EPIRUS Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NovAccess Global position performs unexpectedly, EPIRUS Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will offset losses from the drop in EPIRUS Biopharmaceutica's long position.

The idea behind NovAccess Global and EPIRUS Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.